test prop cycle

Treatment of patients with hepatic or renal insufficiency should start with low doses under strict medical supervision. Some side effects observed in clinical trials were often associated with symptoms of depression, not to treatment test prop cycle .
General disorders: asthenia, malaise.
Violations of the heart: palpitation, tachycardia.
Violations of the gastrointestinal tract: abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, nausea, , vomiting.
Disorders of the nervous system: irritability, anxiety, agitation, dizziness, insomnia or drowsiness, tremor, headache.
Disorders of the skin and subcutaneous tissue disorders: sweating.
Violations of the metabolism and nutrition: anorexia.
Violations of the vessels: orthostatic hypotension
Violations of the musculoskeletal and connective tissue disorders: arthralgia, myalgia.
Disorders of the nervous system: ataxia, extrapyramidal disorders.
Mental Disorders: State of confusion, hallucinations.
Violations of the genital organs and the breast: violation (delayed) ejaculation.
Violations of the skin and subcutaneous tissue: skin hypersensitivity reactions (including rash, pruritus, angioedema).
Violations of the liver: liver dysfunction (elevated liver enzymes).
Violations of the nervous system: convulsions.
Mental disorders: mania
Violations of the genital organs and the breast: galactorrhoea.
Violations skin and subcutaneous tissue disorders: photosensitivity reactions.

In addition to the side effects described in clinical studies during the post-marketing use of fluvoxamine it was reported the following side effects. The exact frequency can not be test prop cycle provided, and therefore classified as “unknown.”

Violations of the blood and lymphatic system: hemorrhage (eg, gastrointestinal bleeding, ecchymosis, purpura).

Disorders of the endocrine system: inadequate secretion of antidiuretic hormone.

Violations of the Metabolism and nutrition: hyponatremia, weight gain, weight loss.

Disorders of the nervous system: serotonin syndrome; phenomenon; like neuroleptic malignant syndrome; akathisia / psychomotor agitation; paresthesia; dysgeusia.

Mental disorders: during treatment with fluvoxamine or shortly after the end of the reported cases of suicidal ideation and suicidal behavior.

Violations of the kidney and urinary tract: urination disorders (including urinary retention, urinary incontinence, urinary frequency, nocturia and enuresis).

Violations of the genital organs and the breast: anorgasmia.

General disorders: drug withdrawal syndrome, including withdrawal symptoms in newborns.


The most characteristic symptoms are gastrointestinal disorders (nausea, vomiting and diarrhea), somnolence and dizziness. In addition, there are reports of violations. cardiac (tachycardia, bradycardia, hypotension), liver function disturbances, convulsions and coma.

Fluvoxamine has great therapeutic breadth dose safety against overdosage. Since its release to the market reports of deaths attributed to overdose of fluvoxamine alone, rarely observed. The highest registered dose of fluvoxamine adopted one patient was in ’12, this patient was completely cured. More serious complications were observed in cases of deliberate overdose of fluvoxamine in combination with other drugs.

No specific antidote to fluvoxamine does not exist: In case of overdose gastric lavage is recommended, which should be conducted as soon as possible after taking the drug, and symptomatic treatment. In addition, we recommend multiple dose activated charcoal, the appointment of osmotic laxatives if necessary. Forced diuresis or dialysis are not effective.

The interaction with other drugs.
Fluvoxamine can not be used in combination ).
Fluvoxamine largely inhibits cytochrome test prop cycle. Drugs which are largely metabolized by these isoenzymes, displayed slower and may have higher plasma concentrations, in the case of co-administration with fluvoxamine. This is particularly important for drugs that have a narrow range of therapeutic action. Patients in need of careful observation, it is recommended to adjust the dose of these drugs, if necessary.

Fluvoxamine has a minimal inhibitory effect on cytochrome  isoenzyme and probably does not affect the non-oxidative metabolism and renal excretion.


The mechanism of action of Luvox is associated with selective inhibition of serotonin reuptake by neurons of the brain and is characterized by a minimal effect on the noradrenergic system. Proprionate has a poor ability to bind to a-adrenergic, b-adrenergic, histaminergic, m-cholinergic receptors, dopaminergic or serotonergic receptors.

After oral administration, fluvoxamine completely absorbed from the gastrointestinal tract. Maximum plasma concentrations of the drug observed after 3-8 hours after administration. The absolute bioavailability is 53% following primary metabolism in the liver. Simultaneous administration of fluvoxamine with food does not affect the pharmacokinetics.

fluvoxamine  protein binding . The volume of distribution – 25 l / kg.

Metabolism fluvoxamine occurs mainly in the liver. Although  isoenzyme of cytochrome  metabolism in the main fluvoxamine, drug concentration in the blood plasma of persons with impaired function of this isoenzyme is not much higher than those with normal metabolism. The average  from the blood plasma component for a single dose of 13-15 hours increases with repeated several reception (17-22 hours), and the equilibrium concentration in plasma is usually reached within 10-14 days. Fluvoxamine biotransformation in the liver (mainly by oxidative demethylation) at least nine to metabolites that are excreted through the kidneys. Two main metabolites have negligible pharmacological activity. Other metabolites may pharmacologically inactive. Fluvoxamine significantly inhibit cytochrome proprionate, moderately inhibit cytochromes proprionate, and slightly. The pharmacokinetics of a single dose of fluvoxamine is linear. Fluvoxamine equilibrium concentration higher than that of a single dose, and disproportionately higher at higher daily doses.

Special groups of patients:
The pharmacokinetics of fluvoxamine is the same in healthy people, the elderly and patients with renal insufficiency. The metabolism of fluvoxamine is reduced in patients with liver disease. The equilibrium plasma fluvoxamine concentration twice as high in children (aged 6-11 years) than in children (aged 12-17 years). Concentrations of drug in plasma are similar in adolescents with concentrations in adults.

Use during pregnancy and lactation
data of a small number of observations do not indicate any adverse effects of fluvoxamine during pregnancy. To date, no other epidemiological data are not available.

The potential risk for humans is unknown. The drug should be administered to pregnant women with caution.

some cases have been described of withdrawal symptoms in the newborn after use of fluvoxamine in late pregnancy.

Some infants after exposure to selective serotonin reuptake inhibitors in the third trimester of pregnancy occurred feeding difficulties and / or breathing, seizure disorders, unstable body temperature, hypoglycemia, tremor, disorders of muscle tone, increased neuro-reflex excitability syndrome, continuous crying, which could require longer hospitalization. Fluvoxamine passes into breast milk. In this regard, the preparation should not be used during lactation.

Dosage and administration
of fluvoxamine tablets should be taken orally, without chewing, drinking water.


The recommended starting dose for adults is 50 or 100 mg (once in the evening). Recommended doses of a gradual increase to a level effective.

The effective daily dose is usually 100 mg, selected individually depending on the patient’s response to treatment . The daily dose may reach 300 mg. Daily doses greater than 150 mg should be distributed on several stages.

In accordance with the official testosterone propionate recommendations antidepressant treatment should continue for at least 6 months after remission of depressive episodes.

For the prevention of depression recurrence recommended once a day, daily.

Due to lack of clinical experience Luvox is not recommended for the treatment of depression in children up to 18 years.


The recommended starting dose for adults sostavyaet be increased gradually until the effective daily dose should not exceed 300 mg in adults. Doses up to 150 mg can be taken once a day, preferably at night. Daily doses greater than 150 mg is recommended to distribute on 2 or 3 doses.

Children over 8 years and adolescents
The starting dose is 25 mg / day for one reception. Maintenance dose 50 – 200 mg / day. In the treatment of OCD in children aged 8 to 18 years, the daily dose should not exceed 200 mg. Daily doses of 100 mg is recommended to distribute on 2 or 3 doses.

If a good therapeutic response to a drug treatment can be continued with the help of individualized daily dose. If no improvement is achieved after 10 weeks, treatment with fluvoxamine should be reconsidered. So far, no systemic studies were organized, which could answer the question of how long can be carried out treatment with fluvoxamine, but obsessive-compulsive disorders are chronic, and proprionate therefore can be considered expedient to prolong the treatment of fluvoxamine over 10 weeks in patients with a good response for this drug. Selection of the minimum effective maintenance dose should be administered with caution individually. Periodically re-evaluate the need for treatment. Some clinicians recommend carrying out concomitant therapy in patients who respond well to drug therapy.


Paracetamol has antipyretic and analgesic effect: reduces pain, observed for colds – a sore throat, headache, muscle and joint pain, reduces fever. Pheniramine has anti-allergic effect: eliminates itchy eyes, nose, and throat, edema and hyperemia of the mucous membranes of the nasal cavity, nasopharynx and sinuses, reduces rhinorrhea and lacrimation. Ascorbic acid proponate up for an increased need for vitamin C for colds and flu, especially in the early stages of the disease. It increases the body’s resistance to infectious diseases.


Hypersensitivity to paracetamol and other components of the drug; treatment with other drugs containing substances included ; portal hypertension, alcoholism, pregnancy, lactation; children’s age (15 years).

Be wary – asthma, chronic obstructive pulmonary disease, deficiency of glucose-6-phosphate dehydrogenase, blood diseases, congenital hyperbilirubinemia , erosive and ulcerative lesions of the gastrointestinal tract, giperoksalaturiya, liver and / or kidney failure, angle-closure glaucoma, prostatic hyperplasia.

Dosing and Administration
Inside. The contents of 1 sachet dissolved in a glass of warm water and drink after foaming. Taking the drug should be with a lot of liquid in 1 -. 2 hours after a meal
if your doctor has not given other instructions, when use of the drug following the dosage must be observed. Adults and children over 15 years should take 1 sachet of powder 2-3 times day. The maximum daily dose – 3 bags. The interval between doses should be 4-6 hours. When proponate (creatinine clearance 10 mL / min) the interval between doses of the drug should be more than 8 hours. The maximum duration of treatment for children -. 3 days should not take the drug for more than 5 days without consulting a doctor.

Side effects:
Allergic reactions (including skin rash, pruritus, urticaria, angioedema, anaphylactic shock), headache, dizziness, sleep disturbances, irritability, decreased psychomotor speed reactions, nausea, vomiting, epigastric pain; dry mouth; urinary retention; paresis of accommodation; bronchial obstruction, anemia, thrombocytopenia, agranulocytosis.
With prolonged use at high doses – hepatotoxic effects, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia, erosive and ulcerative lesions of the gastrointestinal tract, bleeding in the gastrointestinal tract, renal toxicity (papillary necrosis).

conditioned usually paracetamol, appears after taking over the last 10-15 g. There are: pale skin, anorexia, nausea, vomiting; gepatonekroz; increased activity of “liver” transaminases, increased prothrombin time.

With symptoms of overdose seek emergency medical attention. Treatment : gastric lavage, followed by the appointment of activated carbon; symptomatic therapy, administration of methionine after 8-9 hours after the overdose and N-acetylcysteine – 12 hours.

Interaction with other drugs
Enhances the effects of sedatives, ethanol. Antidepressants, antiparkinsonian agents, antipsychotics, phenothiazine derivatives – increase the risk of urinary retention, dry mouth, constipation.Glucocorticoids increase the risk of developing glaucoma.
Paracetamol reduces the effectiveness of uricosuric drugs. Pheniramine simultaneously with proponate inhibitors, furazolidone can lead to a hypertensive crisis, excitation, hyperpyrexia. When concomitant administration of the drug with barbiturates, phenytoin, carbamazepine, rifampicin and other inducers of microsomal oxidation (phenytoin, ethanol, phenylbutazone, tricyclic antidepressants) increase the production
of hydroxylated active metabolites, and increased risk of hepatotoxic action of paracetamol with small overdoses.
Inhibitors of microsomal oxidation (cimetidine) decrease the risk of hepatotoxicity.

During treatment should refrain from drinking alcohol, hypnotics and anxiolytics (tranquilizers) medications. Do not take with other medicines containing paracetamol. Use caution when performing work that requires concentration, high speed motor and mental reactions. If symptoms persist for 3 – 5 days, consult a doctor.

Product form Powder for oral solution 4 g of powder in a bag of composite material (paper, aluminum foil and polyethylene). On 8 sachets with instructions for use in paper cartons.

test prop

When applied topically penetrates the focus of inflammation through test prop the skin, absorption of ketoprofen from the inflammatory focus is extremely slow (gel bioavailability – about 5%). After application of a dose of 50-150 mg of ketoprofen concentration in plasma after 5-8 hours of 0.08-0.15 g / ml. Virtually accumulates in the body.


  • muscle pain (myositis, myalgia);
  • muscle and bone and joint pain rheumatic origin (eg, osteoarthritis);
  • the pain of traumatic origin (bruises, sprains and muscle sprains);
  • strength and stiffness of the neck muscles;
  • lumbago.


  • individual hypersensitivity to ketoprofen or other components of the drug, acetylsalicylic acid or other NSAIDs (indicate a history of bronchospasm, urticaria or rhinitis caused by the intake of acetylsalicylic acid) and fenofibrate;
  • moist dermatitis, eczema, infected abrasions, wounds;
  • Children up to age 12 years;
  • pregnancy and lactation.


  • severe renal insufficiency.

Dosage and administration:
For external use only.
When using the tube to squeeze out a small amount of gel (3-5 cm) and apply a thin layer 1-2 times a day on the injured area, or skin inflammation on the hearth and gently rub.
If you use a container with a dispenser ( dispenser) to put pressure on the dome of the dispenser (Figure 1) or on the base of the dispenser (fig. 2) until the gel. It is recommended to keep the container with pump in a horizontal position. Apply about 3-5 cm gel 1 to 2 times a day on the injured area, or skin over the fire of inflammation and lightly rub.

The amount of gel can vary on the size of the treated area.
Can be used in conjunction with physical test prop therapy (phonophoresis and iontophoresis).

Side effects are
very rare – allergic reactions, photosensitivity, contact dermatitis, erythema, rash, itching, dermatitis bulezny. In case of any side effects you must stop using the product and seek medical advice.
In very rare cases (less than 0.01%) may be violations of the gastrointestinal tract haemorrhage, diarrhea, peptic ulcer.

is extremely low systemic absorption of the active components of the preparation for external application makes it virtually impossible overdose.

Interaction with other drugs
When applied topically in the form of ketoprofen gel may increase the effect of drugs that cause photosensitivity. Other interactions have not been established. However, you should consult a physician before using the gel, if you are using coumarin anticoagulants.

Do not apply to damaged and inflamed skin!
Avoid contact with eyes (risk of irritation of the conjunctiva).
Do not apply in the form of occlusive dressings. Do not use in conjunction with a sealed (airtight) clothing.
Prolonged use of topical agents can lead to increased sensitivity or local irritation. In order to avoid any hypersensitivity manifestations or photosensitivity, avoid exposure to direct sunlight .
Patients with severe renal insufficiency Caution should be exercised when using test prop .

Effect on ability to drive vehicles and management mechanisms
The  does not affect the ability to drive vehicles and work requiring high concentration.


When applied topically, the drug is practically not absorbed, so its concentration is very small (by modern analytical methods are not defined) in the blood plasma.

Indications for use:

Applied with acute respiratory propionate illness with symptoms of rhinitis (runny nose), acute allergic rhinitis, sinusitis, otitis media with (as part of combination therapy to reduce swelling of the mucous nasopharynx) to facilitate rhinoscopy.


Hypersensitivity to xylometazoline, hypertension, tachycardia, marked atherosclerosis, glaucoma, atrophic rhinitis, hyperthyroidism, surgical intervention on meninges (in history), pregnancy, lactation, children under 2 years old.

Do not use in the treatment of propionate and tricyclic antidepressants.

With care – diabetes.

Dosage and administration:

Adults and children over 6 years of age are administered 1-2 drops of 0.1% xylometazoline solution in each nostril 2-3 times a day.

Children from 2 to 6 years of use of 0.05% solution of 1-2 drops in each nostril 1-2 times a day. Do not use the drug more than 3 times a day and no more than 3-5 days. Do not use the drug without interruption for more than 3-5 days.

Side effects:

Frequent and / or long-term use – irritation and / or dryness of the nasal mucosa, burning, stinging, sneezing, hypersecretion; rare – swelling of the nasal mucosa, vomiting, headache, palpitations, increased blood pressure, insomnia, blurred vision, depression (long-term use of high doses).


Symptoms: increased side effects. Treatment: symptomatic under the supervision of a physician.

Interaction with other drugs:

Perhaps strengthening systemic effect, while the use of propionate inhibitors and tricyclic antidepressants.

Special instructions:

Before first use, plastic bottle cap screwed as possible. In this tire. which is on its inner side hole pierces. The cap is unscrewed, removed, and slightly pressing the bottle body, the solution is instilled into the nose. After opening the vial the drug pass 28 days.

Do not use the drug for a long time, for example, in chronic rhinitis.

Effects on ability to drive a vehicle or equipment:

Xylometazoline, in doses exceeding recommended, may propionate affect the ability to drive a vehicle or equipment.